AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intraven...
FDA Drug Recall #D-0226-2017 — Class II — December 15, 2016
Recall Summary
| Recall Number | D-0226-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | December 15, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Amgen, Inc. |
| Location | Thousand Oaks, CA |
| Product Type | Drugs |
| Quantity | 11,434 vials |
Product Description
AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01
Reason for Recall
Lack of Assurance of Sterility: Potential cracks in glass vials
Distribution Pattern
United States and Puerto Rico No foreign distribution.
Lot / Code Information
Lot #1071559, 1071629; Exp. 05/18
Other Recalls from Amgen, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0285-2025 | Class II | Neupogen (filgrastim) For Injection, 300mcg/1 m... | Feb 27, 2025 |
| D-0286-2025 | Class II | Neupogen (filgrastim) For Injection, 480 mcg/1.... | Feb 27, 2025 |
| D-0855-2022 | Class II | MVASI (bevacizumab-awwb), Injection, For Intrav... | May 2, 2022 |
| D-1173-2017 | Class II | Procrit (epoetin alfa), 10,000 units/mL, packag... | Sep 13, 2017 |
| D-1086-2017 | Class II | Procrit Epoetin Alfa 40,000 units/mL single use... | Aug 4, 2017 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.